Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

al revenue has been classified as research and

development revenue under collaborative agreements on Isis' condensed

consolidated statement of operations.

(2) Ibis' cost of commercial revenue has been classified as research and

development expenses on Isis' condensed consolidated statement of

operations.

Regulus Therapeutics LLC

Statements of Operations

(In Thousands)

Three Months Six Months

Ended Ended

June 30, 2008 June 30, 2008

Revenue:

Research and development revenue under

collaborative agreements $656 $748

Total revenue 656 748

Expenses:

Research and development 1,606 2,918

General and administrative 917 1,132

Total operating expenses 2,523 4,050

Loss from operations $(1,867) $(3,302)

Regulus was formed in the third quarter of 2007; therefore it does not have operating results for the first half of 2007.

Isis Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In Thousands)

June 30, December 31,

2008 2007

(unaudited)

Assets:

Cash, cash equivalents and short-term

investments $536,969 $193,719

Other current assets
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
(Date:4/16/2015)... MENLO PARK, Calif. , April 16, 2015 /PRNewswire/ ... the Company), a biopharmaceutical company focused on developing and ... today announced that the Mayo Clinic Cancer Center ... for the ongoing, multicenter Phase I/II study of VAL-083 ... common and deadly form of human brain cancer. ...
(Date:4/16/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... DCVax® personalized immune therapies for cancer, announced today ... Cancer Immunotherapy Index (LCINDX), a professional index recently ... field within the biotechnology space.  ... companies" in the immunotherapy space, including 6 big ...
(Date:4/16/2015)... Tex. (PRWEB) April 16, 2015 ... chain management systems for highly regulated industries, is ... been name a monthly columnist for Cold Chain ... ( http://www.coldchainiq.com ). His column titled, Global Cold ... chain information for today’s life sciences, pharmaceutical and ...
Breaking Biology Technology:Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... , PHILADELPHIA, Aug. 26 ERT (Nasdaq: ... Associate Director of Business Development - Japan, Miki Stevens. In ... partner, Site Support Institute (SSI), to facilitate sales activities and ... trial sites. By nurturing existing strategic partnerships, Ms. Stevens will ...
... ... community to obtain relevant information and accuracy beyond Search Engine Optimization , ... Malaga, Spain (Vocus) August 26, ... software solutions, will present on September 1st at the Association for Medical Education ...
... , , ... it has received 510K Clearance from the FDA for its ... the device in the United States. Aixplorer is the ... which is based upon interaction between conventional longitudinal waves and ...
Cached Biology Technology:ERT Appoints New Associate Director of Business Development - Japan 2ERT Appoints New Associate Director of Business Development - Japan 3iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference 2SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 2SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 3SuperSonic Imagine Receives FDA Approval for Aixplorer Ultrasound System 4
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/143028 for MINIATURE, MULTI-PURPOSE ... TRANSFER  NXT-ID introduces a new revolutionary ... patent surrounds the use of miniature antenna modules ...
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... adopts an unusual shape called Z-DNA, it can lead to ... leukemia and lymphoma, according to a study by researchers at ... , The study, issued in advance of the Feb. 21 ... demonstrates for the first time that the oddly shaped DNA ...
... individuals of many fish species face a developmental choice ... a sedentary or migratory lifestyle. , Sedentary (or ... while their migratory compatriots set forth on long open-water ... "life history" is known to be influenced by environmental ...
... restricting antibiotic use in food-producing animals may be linked ... citizens, according to an article in the May 15 ... , Campylobacter jejuni is a leading bacterial cause of ... Campylobacter infections difficult for physicians to treat, and can ...
Cached Biology News:When good DNA goes bad 2When good DNA goes bad 3For some young fish, early gene expression is a clear harbinger of fated lifestyle 2Less antibiotic use in food animals leads to less drug resistance in people, study shows 2